Trials / Recruiting
RecruitingNCT06031805
PRostate Olaparib Real World Evidence Study
a French Observational Prospective Multicenter Study of Adult Patients Treated in the Real-life Setting With Olaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This French non-interventional prospective multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
Conditions
Timeline
- Start date
- 2023-10-11
- Primary completion
- 2028-10-13
- Completion
- 2028-10-13
- First posted
- 2023-09-11
- Last updated
- 2025-10-28
Locations
65 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06031805. Inclusion in this directory is not an endorsement.